Alseres Pharmaceuticals Announces 12 Month Interim Results From The Phase I/IIa Cethrin(R) Clinical Trial In Acute Spinal Cord Injury
May 15th 2008Drug InformationClinical Trials
Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE) announced 12-month interim data from its Phase I/IIa clinical trial of Cethrin, a proprietary recombinant protein that is being investigated for its potential to restore motor and sensory function after spinal cord injury, or SCI. The trial enrolled a total of 48 patients of which 37 have reached the final 12 month follow up evaluation.
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
